LGND

Ligand Pharmaceuticals Inc

Company with tickers: LGND, LGNDZ, LGNXZ, LGNYZ, LGNZZ

CIK

886163

CUSIP

53220K504

Shares Outstanding

20,041,061

Website

https://www.ligand.com

Investor Relations

https://investor.ligand.com/overview/default.aspx

13F Activity (30d)

30 filings 7 filers

Press releases and events scraped from the company's investor relations website. News and event listings link back to the original source.

Date	Headline
2026-06-10	Ligand Announces 2026 Investor Day in New York City
2026-05-27	Ligand to Participate in June Investor Conferences
2026-05-07	Ligand Reports First Quarter 2026 Financial Results
2026-05-05	Ligand to Participate in May Investor Conferences
2026-04-27	Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand’s Position as a Leading Biopharma Royalty Aggregator
2026-04-22	Ligand to Report First Quarter 2026 Financial Results on May 7, 2026
2026-04-14	Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan) in FSGS
2026-03-26	Ligand Advances Strategic Growth with Expanded and Strengthened Business Development Team
2026-03-04	Ligand to Participate in March Investor Conferences
2026-02-26	Ligand Reports Fourth Quarter and Full Year 2025 Financial Results